StreetAlpha.app
Home › Stocks › DERM

Journey Medical Corp (DERM)

$3.90
▲ +5.41%
LAST CLOSE · NOV 17

Journey Medical sells prescription skin treatments for acne, rosacea and excessive underarm sweating in the United States. It last closed at $3.90 on Nov 17, up 5.41% on the day. The average 12-month price target from 2 analysts is $11.00 (+182.1% from the last close), with a high of $13.00 and a low of $9.00.

AI Auto Pilots
Is DERM in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$69.5M
+17.0% vs a year ago
Net income
−$5.1M
−7.3% margin
EPS (diluted)
−$0.18
Gross margin
65.9%
$45.8M gross profit
Balance sheet
Cash & equivalents
$22.3M
At Sep 30
Debt
$25.6M
At Sep 30
Shareholder equity
$32.2M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $63.1M$63.1MFY2021FY2022: $73.7M$73.7MFY2022FY2023: $79.2M$79.2MFY2023FY2024: $56.1M$56.1MFY2024FY2025: $61.9M$61.9MFY2025

From DERM's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Nov 12
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated DERM in the past 90 days, not enough for a consensus
Average 12-month target
$11.00
▲ 182.1% upside

Based on 2 analysts who set a price target on DERM in the past 90 days. The average target is $11.00, with a high of $13.00 and a low of $9.00, compared with the last close of $3.90.

Low $9.00Avg $11.00High $13.00
Blue marker: last close $3.90
Highest target$13.00
Average target$11.00
Lowest target$9.00
Latest rating changes
B. Riley SecuritiesTarget lowered
Nov 13Buy$15 → $13
Rodman & RenshawInitiated
Sep 25Buy$9
B. Riley SecuritiesReiterated
Aug 13Buy$15
DateFirmActionRatingPrice target
Nov 13B. Riley SecuritiesTarget loweredBuy$15 → $13
Sep 25Rodman & RenshawInitiatedBuy$9
Aug 13B. Riley SecuritiesReiteratedBuy$15
Loading…

Technical Analysis

DERM · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 19% below its 20 day and 47% below its 50 day average. It is 64% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 31), near oversold. The nearest support is the Pivot at $3.76, and the nearest resistance the Pivot R1 at $4.13.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 9.5%/day
Key levels
$9.5652 week high+145.1%
$6.39200 day average+63.8%
$6.35100 day average+62.8%
$5.7350 day average+46.9%
$5.39Swing high (Oct 20)+38.2%
$4.6620 day average+19.5%
$4.13Pivot R1+5.9%
$3.90Last close
$3.76Pivot−3.6%
$3.54Pivot S1−9.2%
$3.4052 week low−12.8%
Indicators
RSI (14)31.08Weak, oversold below 30Neutral
MACD-0.47Below its signal lineBearish
Stochastic16.4Near the bottom of its rangeOversold
ADX (14)45.1Strong downtrend
Williams %R-76.0Oversold below −80, overbought above −20Neutral
CCI (20)-175.9Oversold below −100, overbought above 100Oversold
Rate of change−15.9%Change over 10 sessionsBearish
ATR (14)$0.37Typical daily range, 9.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for DERM

What happened before

See how DERM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow DERM usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How DERM has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in DERM in the last 90 days.

Loading…

See today’s whale options flow across the market →

DERM Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▼30 buying vs 42 selling
  • ▲Shares held by funds +2.8%
  • ▲Funds holding +3
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding7471+4.2%
In funds' top 1000–
Held by funds–––
New / increased15 / 1523 / 19−28.6%
Reduced / sold out30 / 1223 / 23−8.7%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See DERM institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DERM is in one of them and how their past DERM trades turned out.

DERM in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered DERM in an article yet. Here's the latest on the wider market.

About Journey Medical

Journey Medical sells prescription medicines for skin conditions in the United States. Its main products treat acne, rosacea and excessive underarm sweating, and include brands such as Emrosi, Qbrexza, Accutane and Zilxi. The company also sells older skin and wound care products. It is based in Scottsdale, Arizona, and its sales team markets its products to doctors who prescribe them to patients.

Headquarters
Scottsdale, AZ